The M13 and M20 modules contain both hub genes (kME ≥ 0.7) and differentially significant genes (p < 0.05 and fold change > 1.5) of MM (NEK2, KIF14, CENPF, GABRA3, RRM2, MAGEA6, MAGEA1, HTR2C, and CTAG2) that can be strongly associated with lower overall survival in newly diagnosed MM on RVD treatments. This evidence concerns the gene NEK2 and Miyoshi myopathy.